Association between metabolic syndrome and intravesical prostatic protrusion in patients with benign prostatic enlargement and lower urinary tract symptoms (<scp>MIPS</scp> Study)

Russo, Giorgio Ivan; Regis, F.; Spatafora, Pietro; Frizzi, Jacopo; Urzì, Daniele; Cimino, Silvia; Serni, Sergio; Carini, Marco; Gacci, Mauro; Morgia, Giuseppe

doi:10.1111/bju.14007

Cited by 19 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies have suggested that an inverse association exist between serum T levels and LUTS; however, the underlying biochemical and physiological mechanisms by which reduced T levels affect LUTS have yet to be fully delineated [70717273]. A significantly larger prostate volume was reported in men afflicted with Met S [1921747576], however it is unclear if this increase in prostate volume indeed exerts a clinical significance [32]. Met S which was associated with decreased improvement of postoperative symptoms and LUTS after prostate surgery, suggesting interplay of multiple metabolic risk factors contributing to this complex disorder [77].…”

Section: Metabolic Syndrome Testosterone Deficiency and Pathophysiomentioning

confidence: 99%

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

Lower urinary tract function is modulated by neural, vascular and urethral and bladder structural elements. The pathophysiological mechanisms of lower urinary tract symptoms (LUTS) encompass prostate enlargement, alterations in urethra histological structure bladder fibrosis and alterations in pelvic neuronal and vascular networks, The complex pathophysiological relationship between testosterone (T) deficiency (TD) and the constellations LUTS, and metabolic dysfunction manifested in the metabolic syndrome (Met S) remains poorly understood. TD has emerged as one the potential targets by which Met S may contribute to the onset and development as well as worsening of LUTS. Because it has been recognized that treatment of men with Met S with T therapy ameliorates Met S components, it is postulated that T therapy may represent a therapeutic target in improving LUTS. Furthermore, the effect of TD on the prostate remains unclear, and often debatable. It is believed that T exclusively promotes prostate growth, however recent evidence has strongly contradicted this belief. The true relationship between benign prostatic hyperplasia, TD, and LUTS remains elusive and further research will be required to clarify the role of T in both benign prostatic hypertrophy (BPH) and LUTS as a whole. Although there is conflicting evidence about the benefits of T therapy in men with BPH and LUTS, the current body of literature supports the safety of using this therapy in men with enlarged prostate. As the population afflicted with obesity epidemic continues to age, the number of men suffering from Met S and LUTS together is expected to increase.

show abstract

Section: Metabolic Syndrome Testosterone Deficiency and Pathophysiomentioning

confidence: 99%

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

show abstract

“…2 Furthermore, contrary to previous studies, the prostate volume of patients with MetS was comparable with those without MetS. 3,4 Maybe, as the authors mentioned, the significant difference between the participants of two groups might prevent reliable comparison in this regard.Consequently, this study gives significant clues, but the current evidence is insufficient to arrive at a coherent conclusion on the implication of MetS and its components on the early acquisition of urinary incontinence after robot-assisted radical prostatectomy. The present study provides remarkable insights, yet new prospective or cohort studies with more extensive participants are clearly required to better establish the causality.…”

mentioning

confidence: 83%

mentioning

confidence: 84%

Re: Impact of metabolic syndrome on early recovery of continence after robot‐assisted radical prostatectomy

Beşiroğlu

2018

Int J of Urology

View full text Add to dashboard Cite

“…Lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS) are two of the most common diseases of the aging male, with a high impact on the world economy, due to their association with increased morbidity and mortality (Fenter et al ., ; Misra & Khurana, ; Parsons et al ., ; Vuichoud & Loughlin, ; Egan, ; La Vignera et al ., ). In particular, many clinical studies have demonstrated an association between MetS and prostatic disease, including LUTS and BPH (Moul & McVary, ; Parsons et al ., ; Russo et al ., ). In two recent meta‐analysis, authors found a close link between prostate volume and MetS, and in particular, they found that obesity, dyslipidemia, and age increased the risk of having MetS (Gacci et al ., ; Russo et al ., ,b).…”

Section: Introductionmentioning

confidence: 97%

Benign prostatic hyperplasia and intraprostatic inflammation are associated with liver inflammation: it's time for prevention

et al. 2018

View full text Add to dashboard Cite

Some evidences have supported the link between benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and inflammation. In this study, we aimed to evaluate the association between prostatic inflammation (PI) and non-alcoholic steatohepatitis (NASH) evaluated by a non-invasive scores in a cohort of patients affected by BPH/LUTS. Between January 2012 and January 2016, we conducted a prospective study in a single academic outpatient clinic on 132 consecutive patients who underwent surgery for lower urinary tract symptoms (LUTS) due to bladder outlet obstruction (BOO). A non-invasive non-alcoholic steatohepatitis score (NASH score) was calculated, and PI was evaluated through the Irani score. Patients with a NASH score > 1.05 had an average larger prostate volume (55 vs. 45 cc, p < 0.05), a greater waist circumference (103 vs. 93.5 cm, p < 0.01), and high values of blood glucose, triglycerides, insulin, and BMI compared to patients without NASH; 36% of patients with an Irani score ≥ 4 had NASH compared to 16.1% of patients who had a NASH score < 1.05 (p < 0.05). We found that non-alcoholic steatohepatitis (NASH ≥ 1.05) was an independent risk factor for Irani score ≥4 (OR: 3.24; p < 0.05) and of prostate volume ≥ 40 cc (OR: 13.99; p < 0.01). LUTS/BPH and NASH can be closely related, underlying common triggers of induction. In particular, inflammation seems to be associated with both conditions and with prostate gland overgrowth. Early identification of this class of patients could play a key role in preventing complications related to disease progression.

show abstract

Association between metabolic syndrome and intravesical prostatic protrusion in patients with benign prostatic enlargement and lower urinary tract symptoms (MIPS Study)

Abstract: We found an association between MetS and BPE, demonstrating a relationship with IPP.

Cited by 19 publications

References 26 publications

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Re: Impact of metabolic syndrome on early recovery of continence after robot‐assisted radical prostatectomy

Benign prostatic hyperplasia and intraprostatic inflammation are associated with liver inflammation: it's time for prevention

Contact Info

Product

Resources

About